BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.341
+0.026 (8.12%)
At close: Dec 20, 2024, 4:00 PM
0.342
+0.001 (0.26%)
After-hours: Dec 20, 2024, 7:10 PM EST
BioXcel Therapeutics Employees
BioXcel Therapeutics had 74 employees as of December 31, 2023. The number of employees decreased by 109 or -59.56% compared to the previous year.
Employees
74
Change (1Y)
-109
Growth (1Y)
-59.56%
Revenue / Employee
$30,757
Profits / Employee
-$959,405
Market Cap
14.58M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
ProPhase Labs | 113 |
ImmunoPrecise Antibodies | 101 |
Ekso Bionics Holdings | 72 |
GlycoMimetics | 35 |
Traws Pharma | 18 |
Innovative Eyewear | 11 |
Minerva Neurosciences | 9 |
Acurx Pharmaceuticals | 4 |
BTAI News
- 4 weeks ago - BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewsWire
- 4 weeks ago - BioXcel Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 5 weeks ago - BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewsWire
- 7 weeks ago - BioXcel Therapeutics to Present at ThinkEquity Conference - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire